Novocure (NVCR) announced that the FDA approved its new head flexible electrode, or HFE, transducer arrays for use with Optune Gio for the treatment of adult patients with glioblastoma multiforme, or GBM. Optune Gio is a wearable, portable device that produces alternating electric fields known as Tumor Treating Fields, which are delivered through non-invasive, wearable arrays. TTFields exert physical forces on the electrically charged components of dividing cancer cells, which disrupt the rapid cell division exhibited by cancer cells.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVCR:
- Novocure participates in a conference call with JPMorgan
- Novocure’s Q3 2024 Results Highlight Growth and Innovation
- NovoCure’s Strong Q3 and Leadership Changes in 2024
- Novocure appoints Christoph Brackmann as Chief Financial Officer
- Is NVCR a Buy, Before Earnings?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
